OXBDF | Oxford BioMedicaCompany profile
Company profileUsing our unique LentiVector® delivery platform, we have created a valuable portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. We have strong partnerships with Novartis, Bioverativ (part of the Sanofi Group), Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, Santen and Orchard Therapeutics, providing them with access to our intellectual property, state-of-the-art production facilities and expertise, and, in addition, we have licensed products and technology rights to Boehringer Ingelheim, Sanofi and Axovant. About the CompanyOxford Biomedica is a gene and cell therapy company specialising in the development of gene-based medicines. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
AddressWindrush Court Key Persons / Board of Directors
Videos about Oxford BioMedica | NotesJump to (Finance sites)         ResearchInvestor pagewww.oxb.comIf you are looking for News & events, Press Release, they are available on their Investors Relationssite. Their Official Profiles    Support this projectIf you want to help pay for server cost or for improving this tool. You can send it via Paypal. Social MediaRecommended Books Buy on Amazon While many books explain the how of bitcoin, The Internet of Money delves into the why of bitcoin. Acclaimed information-security expert and author of Mastering Bitcoin, Andreas M. Antonopoulos examines and contextualizes the significance of bitcoin through a series of essays spanning the exhilarating maturation of this technology. |
